Received May 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Three year gap between two doses (Inappropriate schedule of vaccine); This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine on 11-OCT-2021). On 04-MAR-2025, the patient received the 2nd dose of Shingrix. On 11-OCT-2021, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Three year gap between two doses (Inappropriate schedule of vaccine)). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 23-MAY-2025 The reporter reported that a patient received the two doses of Shingrix with a three-year gap, did have to revaccinate. 1st vaccination was on October 11th 2021 and 2nd was on March 04th 2025. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.